Andrew C. Charles, MD

The director of the UCLA Goldberg Migraine Program discussed the advantages, evidence base, and evolving payor support for CGRP-targeting therapies as potentially a first-line option in migraine prevention. [WATCH TIME: 5 minutes]

Bradley Torphy, MD, and Julio R. Vieira, MD, share unmet needs and clinical pearls for the management of migraine.

Experts in headache medicine review novel therapeutic agents under investigation and the evolving treatment landscape for migraine.

Julio R. Vieira, MD, leads a discussion on the importance of follow-up visits for patients with migraine and considerations for switching therapies.

Andrew C. Charles, MD; Bradley Torphy, MD; and Jessica Ailani, MD, review current FDA approved CGRP monoclonal antibodies available for the preventive treatment of migraine.

Experts in headache medicine discuss the role of CGRP-based therapy for migraine prevention.

Drs Bradley Torphy and Jessica Ailani share thoughts on using consensus statements to guide the treatment of migraine.

Sait Ashina, MD, reviews current AHS (American Headache Society) treatment recommendations for the acute and preventive treatment of migraine.

Dr Julio R. Vieira defines acute versus preventive treatment for migraine and highlights the differences in goals of therapy for each.

Sait Ashina, MD, and Jessica Ailani, MD, comment on the importance of individualized treatment regimens for the management of migraine.

Experts in neurology, Drs Julio R. Vieira, Jessica Ailani, and Bradley Torphy review diagnostic tools available for migraine, including patient use of headache diaries.

Jessica Ailani, MD, and Bradley Torphy, MD, discern the signs of migraine and comment on the importance of ensuring accurate diagnosis for patients.

Drs Bradley Torphy and Julio R. Vieira share insight on approaching the diagnosis of migraine as well as current challenges in diagnosis.

Andrew C. Charles, MD; Jessica Ailani, MD; and Sait Ashina, MD, discuss the impact of migraine on a patient’s quality of life and share strategies for reducing the clinical burden of disease.

Andrew C. Charles, MD, and Sait Ashina, MD, provide an overview of the pathophysiology of migraine and discuss its 5 clinical phases.

A panel of expert neurologists shares advice for community neurologists on preventive migraine treatment and exciting therapies to look forward to.

A discussion on when a patient should be referred to a headache specialist for preventive migraine treatment.

Jessica Ailani, MD, details how the phase 3 ADVANCE trial will shape the research of future agents for preventive migraine treatment.

A key opinion leader discusses the use of oral agents for the preventive treatment of migraine.

Dr Christopher Gottschalk shares how the clinical trial data for CGRP monoclonal antibodies affect patient selection for preventive migraine treatment.

A panel of neurologists review clinical trial data on several CGRP monoclonal antibodies for migraine preventive treatment.

Expert neurologists discuss the use of CGRP monoclonal antibodies to prevent migraines.

Stephanie J. Nahas, MD, MSEd, FAHS, FAAN, provides an overview of the use of onabotulinumtoxinA as a preventive migraine treatment.

A thought leader explains how she involves the patient when selecting novel agents to add to a preventive migraine treatment plan.

An introduction to the use of novel agents for preventive migraine therapy.

An expert panel discusses migraine prevention with the use of behavioral therapies such as cognitive behavioral therapy and stress management.

Dr Andrew Charles shares how he eases patient anxieties over lifestyle changes for preventive migraine therapy.

Rebecca Erwin Wells, MD, MPH, details the effectiveness of lifestyle changes for preventative migraine treatment.

A discussion on how to measure the success of preventative migraine treatment.

Key opinion leaders explain the burden of disease that accompanies preventative migraine treatment.